Cristiano Noto1, Vanessa Kiyomi Ota2, Ary Gadelha3, Mariane Nunes Noto1, Décio Sabbatini Barbosa4, Kamila Landucci Bonifácio4, Sandra Odebrecht Nunes4, Quirino Cordeiro1, Sintia Iole Belangero2, Rodrigo Affonseca Bressan3, Michael Maes5, Elisa Brietzke6. 1. Department of Psychiatry, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil; First Episode Psychosis Program, Faculdade de Ciências Médicas da Santa Casa de São Paulo (FCMSCSP), São Paulo, Brazil. 2. Genetics Division, Department of Morphology and Genetics, Universidade Federal de Sao Paulo (UNIFESP), São Paulo, Brazil. 3. Department of Psychiatry, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil. 4. Health Sciences Graduate Program, Health Sciences Center, State University of Londrina (UEL), Brazil. 5. Health Sciences Graduate Program, Health Sciences Center, State University of Londrina (UEL), Brazil; Department of Psychiatry, Chulalongkorn University, Bangkok, Thailand. 6. Department of Psychiatry, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil. Electronic address: elisabrietzke@hotmail.com.
Abstract
BACKGROUND: Schizophrenia is accompanied by increased lipid peroxidation and nitric oxide (NO) levels and by lowered antioxidant levels. However, the effect of antipsychotic agents on these processes remains unclear. The objective of this study is to determine the oxidative stress (OS) status in drug naïve first-episode psychotic patients (FEP) compared to healthy controls and to delineate the effects of risperidone on these biomarkers. METHODS: 51 drug naive FEP patients and 61 healthy controls were enrolled; FEP patients were reassessed 11 weeks after risperidone treatment. Three OS biomarkers, i.e. lipid hydroperoxides - LOOH, NO metabolites - NOx, and advanced oxidation protein products - AOPP, and two antioxidant biomarkers, i.e. total radical-trapping antioxidant parameter - TRAP, and paraoxonase 1 - PON1, were measured. The Positive and Negative Syndrome Scale (PANSS) and the Calgary Depression Scale for Schizophrenia (CDSS) were used to measure symptoms severity. RESULTS: Significantly lower PON1 activity and increased TRAP values were found in FEP patients. There were no significant associations between any of the OS/antioxidant biomarkers and clinical data. Risperidone treatment significantly increased PON1 activity and decreased LOOH levels. These effects of risperidone were not significantly associated with the clinical response and risperidone dosage. DISCUSSION: Changes in antioxidant profile, but not in lipid or protein oxidation or increased NO production, were found in drug-naive FEP. Risperidone may have antioxidant effects by lowering lipid peroxidation and increasing the antioxidant defenses against lipid peroxidation related to PON1. None of the biomarkers predicted treatment outcome.
BACKGROUND:Schizophrenia is accompanied by increased lipid peroxidation and nitric oxide (NO) levels and by lowered antioxidant levels. However, the effect of antipsychotic agents on these processes remains unclear. The objective of this study is to determine the oxidative stress (OS) status in drug naïve first-episode psychoticpatients (FEP) compared to healthy controls and to delineate the effects of risperidone on these biomarkers. METHODS: 51 drug naive FEP patients and 61 healthy controls were enrolled; FEP patients were reassessed 11 weeks after risperidone treatment. Three OS biomarkers, i.e. lipid hydroperoxides - LOOH, NO metabolites - NOx, and advanced oxidation protein products - AOPP, and two antioxidant biomarkers, i.e. total radical-trapping antioxidant parameter - TRAP, and paraoxonase 1 - PON1, were measured. The Positive and Negative Syndrome Scale (PANSS) and the Calgary Depression Scale for Schizophrenia (CDSS) were used to measure symptoms severity. RESULTS: Significantly lower PON1 activity and increased TRAP values were found in FEP patients. There were no significant associations between any of the OS/antioxidant biomarkers and clinical data. Risperidone treatment significantly increased PON1 activity and decreased LOOH levels. These effects of risperidone were not significantly associated with the clinical response and risperidone dosage. DISCUSSION: Changes in antioxidant profile, but not in lipid or protein oxidation or increased NO production, were found in drug-naive FEP. Risperidone may have antioxidant effects by lowering lipid peroxidation and increasing the antioxidant defenses against lipid peroxidation related to PON1. None of the biomarkers predicted treatment outcome.
Authors: Jonathan L Hess; Daniel S Tylee; Rahul Barve; Simone de Jong; Roel A Ophoff; Nishantha Kumarasinghe; Paul Tooney; Ulrich Schall; Erin Gardiner; Natalie Jane Beveridge; Rodney J Scott; Surangi Yasawardene; Antionette Perera; Jayan Mendis; Vaughan Carr; Brian Kelly; Murray Cairns; Ming T Tsuang; Stephen J Glatt Journal: Schizophr Res Date: 2019-08-04 Impact factor: 4.939
Authors: Mehmet Güneş; Mehmet Akif Camkurt; Mahmut Bulut; Süleyman Demir; Aslıhan Okan İbiloğlu; Mehmet Cemal Kaya; Abdullah Atlı; İbrahim Kaplan; Aytekin Sir Journal: Clin Psychopharmacol Neurosci Date: 2016-11-30 Impact factor: 2.582
Authors: Kärt Kriisa; Liina Haring; Eero Vasar; Kati Koido; Sven Janno; Veiko Vasar; Kersti Zilmer; Mihkel Zilmer Journal: Oxid Med Cell Longev Date: 2016-07-27 Impact factor: 6.543